Literature DB >> 30154078

Stability of thyroid function in older adults: the Birmingham Elderly Thyroid Study.

Lesley Roberts1, Deborah McCahon2, Oliver Johnson3, M Sayeed Haque4, James Parle5, Fd Richard Hobbs6.   

Abstract

BACKGROUND: Thyroid function tests (TFTs) are among the most requested tests internationally. However, testing practice is inconsistent, and potentially suboptimal and overly costly. The natural history of thyroid function remains poorly understood. AIM: To establish the stability of thyroid function over time, and identify predictors of development of overt thyroid dysfunction. DESIGN AND
SETTING: Longitudinal follow-up in 19 general practices in the UK.
METHOD: A total of 2936 participants from the Birmingham Elderly Thyroid Study (BETS 1) with a baseline TFT result indicating euthyroid or subclinical state were re-tested after approximately 5 years. Change in thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroid status between baseline and follow-up was determined. Predictors of progression to overt dysfunction were modelled.
RESULTS: Participants contributed 12 919 person-years; 17 cases of overt thyroid dysfunction were identified, 13 having been classified at baseline as euthyroid and four as having subclinical thyroid dysfunction. Individuals with subclinical results at baseline were 10- and 16-fold more likely to develop overt hypothyroidism and hyperthyroidism, respectively, compared with euthyroid individuals. TSH and FT4 demonstrated significant stability over time, with 61% of participants having a repeat TSH concentration within 0.5 mIU/L of their original result. Predictors of overt hypothyroidism included new treatment with amiodarone (odds ratio [OR] 92.1), a new diagnosis of atrial fibrillation (OR 7.4), or renal disease (OR 4.8).
CONCLUSION: High stability of thyroid function demonstrated over the 5-year interval period should discourage repeat testing, especially when a euthyroid result is in the recent clinical record. Reduced repeat TFTs in older individuals is possible without conferring risk, and could result in significant cost savings. © British Journal of General Practice 2018.

Entities:  

Keywords:  ageing; general practice; primary health care; subclinical thyroid dysfunction; symptoms; thyroid function test

Mesh:

Year:  2018        PMID: 30154078      PMCID: PMC6145980          DOI: 10.3399/bjgp18X698861

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  24 in total

1.  A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study.

Authors:  J Parle; L Roberts; S Wilson; H Pattison; A Roalfe; M S Haque; C Heath; M Sheppard; J Franklyn; F D R Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2010-05-25       Impact factor: 5.958

2.  Spontaneous normalization of thyrotropin concentrations in patients with subclinical hypothyroidism.

Authors:  Juan J Díez; Pedro Iglesias; Kenneth D Burman
Journal:  J Clin Endocrinol Metab       Date:  2005-04-05       Impact factor: 5.958

3.  Observations concerning the natural history of subclinical hyperthyroidism.

Authors:  Kenneth A Woeber
Journal:  Thyroid       Date:  2005-07       Impact factor: 6.568

Review 4.  Age- and race-based serum thyrotropin reference limits.

Authors:  Martin I Surks; Laura Boucai
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 5.  Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.

Authors:  Martin I Surks; Eduardo Ortiz; Gilbert H Daniels; Clark T Sawin; Nananda F Col; Rhoda H Cobin; Jayne A Franklyn; Jerome M Hershman; Kenneth D Burman; Margo A Denke; Colum Gorman; Richard S Cooper; Neil J Weissman
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

6.  Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure.

Authors:  Juan J Díez; Pedro Iglesias
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

7.  Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit.

Authors:  R Eggertsen; K Petersen; P A Lundberg; E Nyström; G Lindstedt
Journal:  BMJ       Date:  1988-12-17

8.  Natural history of subclinical hypothyroidism with TSH ≤10 mIU/l: a prospective study.

Authors:  Pedro W S Rosário; Marina Carvalho; Maria Regina Calsolari
Journal:  Clin Endocrinol (Oxf)       Date:  2015-10-05       Impact factor: 3.478

9.  Prevalence of subclinical hypothyroidism in patients with chronic kidney disease.

Authors:  Michel Chonchol; Giuseppe Lippi; Gianluca Salvagno; Giacomo Zoppini; Michele Muggeo; Giovanni Targher
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-11       Impact factor: 8.237

10.  Elevations of thyroid-stimulating hormone during acute nonthyroidal illness.

Authors:  E T Wong; S G Bradley; A L Schultz
Journal:  Arch Intern Med       Date:  1981-06
View more
  4 in total

1.  Subclinical thyroid dysfunction symptoms in older adults: cross-sectional study in UK primary care.

Authors:  Deborah McCahon; M Sayeed Haque; James Parle; Fd Richard Hobbs; Lesley M Roberts
Journal:  Br J Gen Pract       Date:  2020-02-27       Impact factor: 5.386

2.  Interpreting Elevated TSH in Older Adults.

Authors:  Jennifer S Mammen
Journal:  Curr Opin Endocr Metab Res       Date:  2019-04-25

Review 3.  Towards De-Implementation of low-value thyroid care in older adults.

Authors:  Jennifer M Perkins; Maria Papaleontiou
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-07-22       Impact factor: 3.626

Review 4.  Within-Person Variation in Serum Thyrotropin Concentrations: Main Sources, Potential Underlying Biological Mechanisms, and Clinical Implications.

Authors:  Evie van der Spoel; Ferdinand Roelfsema; Diana van Heemst
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.